Melissa BadamoPrint | February 29, 2024
Adding daratumumab and hyaluronidase-fihj to lenalidomide, bortezomib and dexamethasone reduced the risk of progression.
Read More
Blood Cancers Today Staff WritersPrint | February 8, 2024
Selinexor is an oral inhibitor for the treatment of relapsed or refractory multiple myeloma.
Ching-Hon Pui, MDPrint | February 8, 2024
Dr. Pui, of St. Jude Children’s Research Hospital, discusses his lifelong commitment to being a pediatric oncologist.
Blood Cancers Today Staff WritersPrint | February 8, 2024
CanScan uses low-depth whole-genome sequencing to detect early cancer signals with 99% specificity.
Blood Cancers Today Staff WritersPrint | February 8, 2024
In a clinical trial, relma-cel demonstrated a three-month ORR of 81.36% in patients with relapsed or refractory MCL.
Leah LawrenceMyeloma | February 8, 2024
Researchers are working to define and validate the ways in which mass spectrometry can aid in MM diagnosis and monitoring.
Melissa BadamoPrint | February 8, 2024
This manufacturing process change results in a shorter manufacturing time for axi-cel from 16 days to 14 days.
Blood Cancers Today Staff WritersAcute Myeloid Leukemia | February 8, 2024
Gilead said that it "will not pursue further development of magrolimab in hematologic cancers."
Melissa BadamoPrint | February 7, 2024
The novel GPRC5D-targeted CAR T-cell therapy first gained approval by China’s NMPA following results from the POLARIS ...
Patrick DalyPrint | February 7, 2024
ZUMA-7 showed that axi-cel significantly improved OS compared with standard of care in relapsed or refractory LBCL.
Melissa BadamoPrint | February 5, 2024
Hematologist-oncologists are increasingly turning to podcasts and social media to learn about new data and to share research.
Thomas Martin, MDPrint | February 2, 2024
Thomas Martin, MD, reflects on what's in store for 2024—including the SOHO Annual Meeting, myeloma advancements, and more.
Melissa BadamoAcute Myeloid Leukemia | February 1, 2024
Researchers from St. Jude Children’s Research Hospital developed SJ3149, a selective and potent degrader of CK1α protein.
Blood Cancers Today Staff WritersIndolent B-Cell Lymphoma | February 2, 2024
Cancer Research & Treatment Fund (CR&T) invests in research related to the prevention and treatment of blood cancers.
Leah SherwoodAcute Lymphoblastic Leukemia | January 31, 2024
The past two decades have witnessed a rapid change in the treatment of acute lymphoblastic leukemia.
Mariia Mikhaleva, MDVideo Insights | February 2, 2024
Mariia Mikhaleva MD, a research fellow at the Dana-Farber Cancer Institute, describes how it felt to receive the award.
Patrick DalyMyeloma | January 30, 2024
The CHMP of the European Medicines Agency gave a positive recommendation for the Marketing Authorization approval of ide-cel.
Patrick DalyTransplantation & Cellular Therapy | February 2, 2024
Patients' coping strategies prior to HSCT had significant effects on their psychological distress and quality of life.
Leah SherwoodMyeloma | February 2, 2024
The agency's statement follows potential risks identified by the FDA Adverse Event Reporting System.
Melissa BadamoMyeloma | February 2, 2024
The study aimed to describe the myeloma-defining events and clinical presentations leading to multiple myeloma diagnosis.
Editorial Board